Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
Emilio Merlo Pich, Sergio Melotto
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Sleep and anxiety: From mechanisms to interventions
Sarah L. Chellappa, Daniel Aeschbach
Sleep Medicine Reviews (2021) Vol. 61, pp. 101583-101583
Closed Access | Times Cited: 261
Psychiatric Disorders and Sleep Issues
Eliza L. Sutton
Medical Clinics of North America (2014) Vol. 98, Iss. 5, pp. 1123-1143
Closed Access | Times Cited: 108
Medications for alcohol use disorders: An overview
Mohammed Akbar, Mark Egli, Young‐Eun Cho, et al.
Pharmacology & Therapeutics (2017) Vol. 185, pp. 64-85
Open Access | Times Cited: 86
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner
David E. Moorman, Morgan H. James, Elisabeth A. Kilroy, et al.
European Journal of Neuroscience (2016) Vol. 43, Iss. 5, pp. 710-720
Open Access | Times Cited: 67
The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice
Marcelo F. Lopez, David E. Moorman, Gary Aston‐Jones, et al.
Brain Research (2016) Vol. 1636, pp. 74-80
Open Access | Times Cited: 66
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Open Access | Times Cited: 65
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Erin J. Campbell, Nathan J. Marchant, Andrew J. Lawrence
Brain Research (2018) Vol. 1731, pp. 145902-145902
Closed Access | Times Cited: 50
Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approaches.
Emilio Merlo Pich, Ioannis Tarnanas, Patrizia Brigidi, et al.
Neurobiology of Stress (2025) Vol. 35, pp. 100713-100713
Open Access
Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit
Shingo Soya, Takeshi Sakurai
Brain Research (2018) Vol. 1731, pp. 146037-146037
Open Access | Times Cited: 44
The EEG as an index of neuromodulator balance in memory and mental illness
Costa Vakalopoulos
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 42
Orexin-1 receptor blockade suppresses compulsive-like alcohol drinking in mice
Kelly Lei, Scott A. Wegner, Ji-Hwan Yu, et al.
Neuropharmacology (2016) Vol. 110, pp. 431-437
Open Access | Times Cited: 42
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Glenn Pascasio, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 7, pp. 647-660
Closed Access | Times Cited: 4
Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder
Nicole R. Provenza, Sandesh Reddy, Anthony K. Allam, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 3004-3014
Open Access | Times Cited: 4
Structure–Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT‐462206: a Potent, Brain‐Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist
Christoph Boss, Catherine Roch‐Brisbare, Michel A. Steiner, et al.
ChemMedChem (2014) Vol. 9, Iss. 11, pp. 2486-2496
Closed Access | Times Cited: 38
Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies
Hiroshi Nagase, Naoshi Yamamoto, Masahiro Yata, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 3, pp. 1018-1040
Closed Access | Times Cited: 34
Optical probing of orexin/hypocretin receptor antagonists
Shi‐Bin Li, Natalie Nevárez, William J. Giardino, et al.
SLEEP (2018) Vol. 41, Iss. 10
Open Access | Times Cited: 32
Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
Jessica M. Illenberger, Francisco J. Flores‐Ramirez, Alessandra Matzeu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
Mark K. Greenwald
Neurobiology of Stress (2018) Vol. 9, pp. 84-104
Open Access | Times Cited: 29
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Closed Access | Times Cited: 26
Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial
Susan L. McElroy, Preciosa M. Coloma, Benjamin Berger, et al.
International Journal of Eating Disorders (2023) Vol. 56, Iss. 11, pp. 2120-2130
Open Access | Times Cited: 8
Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses
Santosh Kumar Prajapati, Sairam Krishnamurthy
Behavioural Brain Research (2020) Vol. 399, pp. 113015-113015
Closed Access | Times Cited: 23
Orexin in Patients with Alcohol Dependence Treated for Relapse Prevention: A Pilot Study
M. Ziółkowski, Damian Czarnecki, Jacek Budzyński, et al.
Alcohol and Alcoholism (2015) Vol. 51, Iss. 4, pp. 416-421
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top